Crystagen Peptide 20mg – Protide Health USA

Crystagen Peptide Overview & Technical Specifications

Crystagen peptide is a synthetic short-chain bioregulatory tripeptide associated with the sequence:

Glu-Asp-Pro

or:

EDP

The peptide consists of three amino-acid residues:

• Glutamic acid
• Aspartic acid
• Proline

Protide Health supplies Crystagen peptide as 20mg of 99% purity, HPLC-MS verified, third-party tested lyophilized research material in a 3mL vial.

Crystagen is primarily discussed in the limited short-peptide bioregulator literature involving immune-cell and aging-tissue research.

Technical Specifications

• Product Name: Crystagen
• Alternative Names: Crystagen Peptide, Glu-Asp-Pro, EDP, Glutamyl-Aspartyl-Proline
• Quantity: 20mg
• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified; third-party tested
• Peptide Type: Synthetic bioregulatory tripeptide
• Peptide Length: 3 amino acids
• Sequence: Glu-Asp-Pro
• Molecular Formula: C14H21N3O8
• Molecular Weight: approximately 359.33 g/mol
• Appearance: White to off-white lyophilized powder
• Solubility: Soluble in water
• Storage: Store sealed at ≤6°C and protected from heat, light, and moisture
• Research Use: Short-peptide bioregulation, immune-cell, spleen-aging, biochemical, analytical, and qualified preclinical research only

The formula C14H21N3O8 and molecular weight of approximately 359.33 g/mol are consistent with public chemical records for Glu-Asp-Pro.

Crystagen Identity & Database Caution

The commercial name Crystagen is not consistently linked to a single authoritative chemical database record.

Published and secondary bioregulator literature most often associates Crystagen with:

Glu-Asp-Pro / EDP

However, public chemical records show inconsistencies in stereochemical representation of Glu-Asp-Pro.

Because the supplied product information does not include an independently verified CAS number or authoritative product-specific PubChem identity, Protide Health should avoid adding either identifier until the specific lot documentation confirms them.

For laboratory characterization, the most useful identifiers are:

• Sequence: Glu-Asp-Pro
• Intact molecular mass
• HPLC retention profile
• MS identity
• Purity
• Lot-specific Certificate of Analysis

What Is Crystagen?

The search phrase what is Crystagen generally refers to a short tripeptide bioregulator developed within the Eastern European peptide-bioregulator research tradition.

Its reported sequence is:

Glu-Asp-Pro

Crystagen has been discussed primarily in research involving:

• Immune-cell activity
• Aging spleen models
• B-cell-associated responses
• Short peptide bioregulation
• Tissue-specific signaling

The evidence base is substantially smaller than that available for established peptide hormones or approved peptide therapeutics.

Crystagen Peptide Bioregulator Research

The keyword crystagen peptide bioregulator refers to the broader theory that very short peptides may influence cellular regulatory processes.

Research in this field has proposed possible interactions involving:

• Gene expression
• Cellular differentiation
• Proliferation
• Apoptosis
• Immune-cell signaling
• Age-associated cellular responses

These hypotheses have been investigated across multiple short peptides.

However, evidence involving one bioregulator should not automatically be attributed to Crystagen peptide.

Sequence specificity remains important.

Crystagen & Aging Spleen Research

The most directly relevant indexed study involving Crystagen examined several short peptides in spleen tissue during aging.

The study compared:

• Vilon
• Timogen
• Crystagen
• R-1

The authors reported distinct effects among the peptides.

For Crystagen specifically, the study reported activity involving the B-cell component of the immune system.

Importantly, the same abstract also stated that Crystagen did not affect cell-renewal processes in the aging spleen.

This negative finding is important because it prevents the study from being interpreted as evidence that Crystagen universally reverses age-associated tissue changes.

Crystagen & B-Cell Research

B lymphocytes are an important component of adaptive immunity.

Their biological functions include:

• Antibody production
• Antigen presentation
• Immune memory
• Cytokine signaling

The limited Crystagen literature has discussed experimental effects on the B-cell arm of immune function.

That finding came from a specific aging-spleen model and should not be generalized to claims such as:

• Improved human immunity
• Increased resistance to infection
• Rejuvenation of the immune system
• Prevention of immune aging

Those outcomes have not been established for the Protide Health research product.

Crystagen Peptide Benefits: Evidence Context

The phrase crystagen peptide benefits commonly reflects consumer interest in human outcomes.

The available peer-reviewed literature is too limited to establish human therapeutic benefits.

Research associated with Crystagen has focused on:

• Immune-cell signaling
• B-cell-associated responses
• Aging tissue
• Peptide bioregulation

The available evidence does not establish that Crystagen peptide:

• Strengthens the human immune system
• Prevents infection
• Reverses immune aging
• Extends lifespan
• Treats immunodeficiency
• Provides general anti-aging benefits

Protide Health therefore presents these topics as research areas rather than product claims.

Crystagen Benefits Search Context

The shorter keyword crystagen benefits refers to the same consumer-oriented intent.

The most direct indexed Crystagen study is narrow and preclinical.

It reported a B-cell-associated effect but also reported no Crystagen-induced cell renewal in the aging spleen model.

This means that describing Crystagen as an established immune-restoration or anti-aging peptide would overstate the available evidence.

Crystagen Peptide Dosage Search Context

The phrase crystagen peptide dosage generally concerns human administration.

Protide Health does not provide human dosing instructions.

The 20mg value on this page describes the total amount of research material contained in the vial.

It is not a recommended dose.

No guidance is provided for:

• Human injection
• Oral administration
• Daily use
• Treatment cycles
• Body-weight calculations
• Immune protocols
• Anti-aging protocols
• Reconstitution for human administration

Qualified laboratories should determine experimental concentrations using validated study methods.

Crystagen & Human Evidence Limitations

The public evidence base for Crystagen is especially limited.

Important limitations include:

• Very few indexed publications naming Crystagen
• Heavy reliance on one originating research group
• Limited independent replication
• Lack of large randomized controlled human trials
• Lack of established pharmacokinetic data
• Lack of a modern regulatory-standard safety database

These limitations should be made clear when discussing Crystagen peptide.

Crystagen & Short Peptide Research

Short bioregulatory peptides are typically only two to four amino acids long.

Because of their small size, researchers have investigated whether they may influence:

• Cellular signaling
• Transcription-related systems
• Chromatin-associated processes
• Tissue-specific regulatory pathways

However, these are broad hypotheses within the short-peptide research field.

They should not be presented as confirmed mechanisms of Crystagen unless directly demonstrated for Glu-Asp-Pro.

Crystagen vs Other Bioregulatory Peptides

Crystagen should not be considered interchangeable with other short peptide bioregulators.

Different peptide sequences may have different experimental profiles.

For example:

Epithalon

A tetrapeptide associated with Ala-Glu-Asp-Gly-related regulatory research.

Pinealon

A tripeptide with the sequence Glu-Asp-Arg.

Crystagen

A tripeptide associated with:

Glu-Asp-Pro

Even small sequence changes can alter:

• Charge
• Structure
• Binding interactions
• Cellular transport
• Experimental response

Crystagen & Immunoprotection Terminology

Some literature uses terms such as immunoprotective when discussing Crystagen.

This terminology should be interpreted as an experimental description within specific models.

It does not mean that Crystagen has been clinically proven to protect humans against:

• Infection
• Immune dysfunction
• Age-associated immune decline
• Autoimmune disease

Research terminology and clinical treatment claims are not equivalent.

Crystagen Research Applications

Qualified laboratories may investigate Crystagen peptide in research involving:

• Short-peptide bioregulation
• B-cell-associated signaling
• Immune-cell models
• Spleen-aging models
• Cellular differentiation
• Age-associated signaling
• Peptide transport
• Analytical peptide characterization
• Comparative bioregulator studies

Because the evidence base is small, carefully controlled experimental design is particularly important.

Related Protide Health Research Products

Researchers comparing short bioregulatory peptides may review Epithalon 10mg for a distinct tetrapeptide research system.

The N-Acetyl Epithalon research peptide provides a chemically modified version of a separate short-peptide research model.

Researchers may also examine Pinealon 20mg for a Glu-Asp-Arg tripeptide with a different sequence and research literature.

These products should not be considered chemically or mechanistically interchangeable with Crystagen peptide.

Research Format & Storage

Protide Health supplies Crystagen peptide as:

• Quantity: 20mg
• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified
• Verification: Third-party tested
• Appearance: White to off-white
• Solubility: Soluble in water

Storage specifications:

• Store at ≤6°C
• Keep sealed
• Protect from heat
• Protect from direct light
• Protect from moisture

These specifications describe laboratory storage characteristics only.

Research Limitations

Several limitations should be considered when interpreting Crystagen research:

• The published evidence base is very small.
• Only limited indexed literature directly names Crystagen.
• Much of the research originates from the same research tradition.
• Independent replication is limited.
• No established large-scale human efficacy trials support the product.
• No comprehensive modern human safety profile has been established.
• A single experimental B-cell-associated finding does not establish general immune enhancement.
• The indexed aging-spleen study also reported no Crystagen-induced cell renewal.
• Public chemical records contain naming and stereochemical inconsistencies.
• A product-specific CAS number has not been reliably established from the supplied data.
• The 20mg quantity identifies vial contents rather than a human dose.
• Protide Health Crystagen is not an FDA-approved pharmaceutical product.

For these reasons, Crystagen peptide is supplied strictly for qualified laboratory research.

Literature & Citation Index

Molecular Aspects of Immunoprotective Activity of Peptides in Spleen During the Ageing Process

Year: 2014
Journal: Advances in Gerontology
PMID: 28976144

Research Context: Crystagen, Vilon, Timogen, R-1, aging spleen, immune cells, B-cell-associated activity, proliferation, differentiation, and apoptosis.

The study reported that Crystagen affected the B-cell arm of the immune system but did not cause cell renewal in the aging spleen model.

This is the most directly relevant indexed study located for Crystagen by name.

Researchers can review broader short peptide bioregulator and Crystagen literature indexed by PubMed.

Frequently Asked Questions

What is Crystagen?

Crystagen is a synthetic short peptide bioregulator most commonly associated with the tripeptide sequence Glu-Asp-Pro.

What is Crystagen peptide?

Crystagen peptide is a three-amino-acid research peptide studied primarily in limited immune-cell and aging-tissue models.

What is the Crystagen sequence?

The supplied sequence is:

Glu-Asp-Pro

or:

EDP

What is the molecular formula?

The supplied molecular formula is:

C14H21N3O8

What is the molecular weight?

The molecular weight is approximately:

359.33 g/mol

What is the PubChem CID for Crystagen?

A definitive Crystagen-specific PubChem CID is not included here because public Glu-Asp-Pro records contain naming and stereochemical inconsistencies. Lot-specific analytical identity should be prioritized.

What are Crystagen peptide benefits?

Research has examined immune-cell and aging-tissue responses, but established human Crystagen peptide benefits have not been demonstrated.

What are Crystagen benefits?

The strongest indexed study reports a limited B-cell-associated effect in an aging-spleen model, not established clinical immune or anti-aging benefits.

What is a Crystagen peptide bioregulator?

The term Crystagen peptide bioregulator refers to the classification of Glu-Asp-Pro within a short-peptide research tradition investigating tissue-specific regulatory effects.

What is Crystagen peptide dosage?

Protide Health does not provide human Crystagen peptide dosage instructions. The 20mg value describes total vial contents only.

Is Crystagen an immune treatment?

No. Crystagen has not been established as an approved treatment for immune disorders or immune aging.

Does Crystagen reverse aging?

No established evidence demonstrates that Crystagen reverses human aging.

What purity does Protide Health specify?

Protide Health specifies 99% purity, with HPLC-MS verification and third-party testing.

Is Crystagen intended for human use?

No. It is supplied exclusively for short-peptide bioregulation, immune-cell, biochemical, molecular, analytical, in-vitro, and qualified preclinical research.

Laboratory Terms & Compliance

Laboratory Research Use Only

This Crystagen peptide product is supplied exclusively for laboratory research, short-peptide bioregulation studies, immune-cell investigation, aging-tissue research, analytical testing, biochemical experimentation, molecular studies, in-vitro investigation, and qualified preclinical experimentation.

It is not intended for human or veterinary consumption, immune treatment, anti-aging therapy, infection prevention, medical use, injection, oral administration, diagnostic use, therapeutic use, or clinical administration.

No human dosage, injection schedule, oral-use protocol, immune-treatment protocol, anti-aging protocol, body-weight calculation, treatment cycle, or human-use preparation guidance is provided.

The purchaser is responsible for appropriate laboratory handling, storage, and use under applicable institutional, federal, state, and local requirements.

For research use only.